Detailed Review Of Prospects For Evolent Health Inc. Stock

A share price of Evolent Health Inc. [EVH] is currently trading at $35.85, up down -4.48%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EVH shares have lost -7.89% over the last week, with a monthly amount glided 0.99%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


On 9, September 2022, Evolent Health to Participate in Upcoming Conferences. In a post published today on Yahoo Finance, Evolent Health, Inc. (NYSE: EVH) (“Evolent”), a health care company that delivers proven clinical and related solutions to payers and providers, today announced that Chief Financial Officer John Johnson and Vice President, Investor Relations Seth Frank will participate in upcoming investor conferences.

From an analyst’s perspective:

Evolent Health Inc. [NYSE: EVH] stock has seen the most recent analyst activity on July 29, 2022, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $40. Previously, Guggenheim started tracking the stock with Buy rating on March 30, 2022, and set its price target to $43. On November 18, 2021, upgrade upgraded it’s rating to Overweight and revised its price target to $37 on the stock. BTIG Research initiated its recommendation with a Buy and recommended $20 as its price target on January 07, 2021. KeyBanc Capital Markets downgraded its rating to Sector Weight for this stock on July 06, 2020. In a note dated June 05, 2020, Goldman downgraded an Neutral rating on this stock and revised its target price from $13 to $8.

Evolent Health Inc. experienced fluctuations in its stock price throughout the past year between $21.36 and $39.78. Currently, Wall Street analysts expect the stock to reach $49.00 within the next 12 months. Evolent Health Inc. [NYSE: EVH] shares were valued at $35.85 at the most recent close of the market. An investor can expect a potential return of 36.68% based on the average price forecast.

Analyzing the EVH fundamentals

During the last quarter, Evolent Health Inc. [NYSE:EVH] saw sales of 319.94 billion, an improvement of 44.00%. Gross Margin for this corporation currently stands at +20.97% with Operating Margin at -1.92%, Pretax Margin comes in at -3.28%, and Net Margin reading is -3.34%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.76 points at the first support level, and at 33.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.21, and for the 2nd resistance point, it is at 38.56.

Evolent Health Inc. [EVH] reported earnings per share of $0.12 for its fiscal quarter that ended on 3/30/2022. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were $0.08 per share as compared to estimates of $0.01 per share, a difference of $0.07 representing a surprise of 700.00%.

Ratios To Look Out For

A current ratio of 1.20 is a noteworthy aspect of Evolent Health Inc. [NYSE:EVH]. Further, the Quick Ratio stands at 1.18, while the Cash Ratio is 0.77. Considering the valuation of this stock, the price to sales ratio is 2.62, the price to book ratio is 3.56.

Transactions by insiders

Insider trading, which has resulted in 4 insider purchases of 231,582 shares and 6 insider sales of 242,520 shares in the past three months, is now the topic of our analysis. Recent insider trading involved Scott Cheryl, Director, that happened on Aug 31 when 3100.0 shares were sold. Director, WILLIAMS FRANK J completed a deal on Aug 24 to sell 50000.0 shares. Meanwhile, Director WILLIAMS FRANK J sold 0.15 million shares on Aug 23.